Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ARM & HAMMER BAKING POWDER TOOTHPASTE AND TOOTH POWDER products are testing in southeastern U.S. markets and in Colorado. Marketed by Arm & Hammer baking soda manufacturer Church & Dwight, the two Dental Care products contain the active ingredient sodium fluoride as well as sodium bicarbonate. The powder alone is also test marketing in Washington State and Wisconsin. The power has been testing for approximately two years; the toothpaste has been testing for less time. The products, Church & Dwight's first specifically for dental care, have patented formulas and are promoted as plaque fighters. Packaging for the toothpaste notes that "more dentists and hygienists recommend brushing with baking soda as part of a program for healthier teeth and gums." In a submission to FDA about one year ago, Church & Dwight sought to demonstrate the safety and efficacy of fluoride tooth powders in order that the formulation be included in the OTC anticaries monograph. The firm told the agency that fluoride in tooth powder is "at least as available to the tooth" as fluoride in toothpaste. Princeton, New Jersey-based Church & Dwight is also promoting the dental care benefits of its Arm & Hammer baking soda alone. Baking soda boxes are flagged on front panels with the announcement: "Important news . . . baking soda is proven to remove plaque." Back panels note that baking soda is "clinically proven to remove plaque" and list instructions for brushing.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts